Fantastic to have ⁦Judy Beveridge 🌻⁩ talking about patient and public involvement in MS-STAT2 😊😊

Rachael Hunter presenting fascinating but quite shocking data on the impact of #SPMS on employment and quality of life for people in MS-STAT2. This is why we need treatments!

Fantastic to have team MS-STAT2 at #MSFrontiers! Congratulations to ⁦⁦MS Society UK⁩ for a brilliant conference in beautiful Swansea!

😂😂

Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial - PubMed pubmed.ncbi.nlm.nih.gov/35946107/

Higher serum neurofilament light chain (sNfL) is linked to more cognitive decline in MS. Data from the MS-STAT study (simvastatin vs. placebo in progressive MS) pubmed.ncbi.nlm.nih.gov/35946107/

How did we recruit all our fantastic volunteers with SPMS for the MS-STAT2 and MS-SMART trials?? How can we make it better?! All in here if interested 👇 trialsjournal.biomedcentral.com/articles/10.11…

#MSAwarenessWeek - how does MS make you feel? Does it affect you personally, or someone you know? Our amazing colleague Dr Alessia Bianchi Alessia Bianchi completing the London marathon to fundraiser for the MS Society UK! If you'd like please donate via: 2023tcslondonmarathon.enthuse.com/pf/alessia-bia…

Hot off the press! The first STAT2 research paper - Cardiovascular Risk Factors in SPMS and how they impact brain volumes and memory. onlinelibrary.wiley.com/doi/full/10.11… Thank you to all our participants for their time and contribution!

The European Academy of Neurology 2023 conference! Let's talk #MS #BigData #Biomarkers #SmoulderingMS #clinicaltrials #PIRA and much more!

#BigData in #MS - so many exciting opportunities to dive deeper into phenotypes, personalised assessments, and enhance clinical trials!

#BigData in #MS - a great overview of the incorporation of all the -omics (genomic, metabolomics, proteomics, etc) towards novel understanding and treatments for #PMS #ProgressiveMS

#BrainAtrophy and #CognitiveImpairment in #MS - Closely interlinked, and of great importance to PWMS. Cognitive impairment being associated with more care needs and worse quality of life - focus on slowing/stopping this is essential!

An excellent overview of #SMOULDERINGMS - how we see progression independent of relapses #PIRA, what processes are involved and what #biomarkers will let us ultimately lead to individualized treatment!

What is MS progression? Our understanding of progress independent of disease activity (PIRA) has grown over the last 20 years, with clinical and real world studies confirming that once relapses are controlled with DMTs progression can still happen!

Great to be in Budapest for #EAN2023 discussing PIRA, compartmentalized CNS inflammation and BTK inhibitors with Veronica Popescu and Marton König Veronica Popescu European Academy of Neurology

Excellent European Academy of Neurology #EAN2023 update on our expanded knowledge of #MS CNS compartmentalised inflammation and the exciting near future of BTK Inhibitors by Wallace Brownlee, Veronica Popescu and Martin König Wallace Brownlee Veronica Popescu

Thank you Stuart Nixon MBE+Marie for inspiring work MS Society UK MS Society Cymru Ambassadors for people with #MS #AdvancedMS Check out chariotms.com #ChariotMS QueenSquareMSCentre MS-STAT2 OctopusTrial AttackMS the_MSBlog #MS Rachel Horne theMSguide.com 🧠 Patrick B, I walk very slowly #NHS75 #GIG75

Registration and abstract submission are open for MS Frontiers conference! This year the MS Society are hosting their MS research conference at the University of Liverpool. Find out all about it and how to register via their website: mssociety.org.uk/research/for-r…

Today the results of the MS-STAT2 trial were announced by Professor Jeremy Chataway at the ECTRIMS research conference in Copenhagen. This trial tested simvastatin, commonly used to treat high cholesterol, in 964 people with secondary progressive MS. (1/6)